Psychopharm review : timely reports in psychopharmacology and device-based therapies最新文献_第5页

Transcranial Magnetic Stimulation for the Treatment of Major Depression: Clinical, Economic, and Practical Issues Part II 经颅磁刺激治疗重度抑郁症:临床、经济和实际问题第二部分

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2010-08-01 DOI: 10.1097/01.IDT.0000384050.93852.3e

M. Demitrack

引用次数: 0

Treatment of Attention Deficit Hyperactivity Disorder in Children With Medical Comorbidities 儿童注意缺陷多动障碍合并症的治疗

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2010-07-01 DOI: 10.1097/01.IDT.0000377465.94323.2d

A. Kledzik, D. Dunn

{"title":"Treatment of Attention Deficit Hyperactivity Disorder in Children With Medical Comorbidities","authors":"A. Kledzik, D. Dunn","doi":"10.1097/01.IDT.0000377465.94323.2d","DOIUrl":"https://doi.org/10.1097/01.IDT.0000377465.94323.2d","url":null,"abstract":"der (ADHD) in children was analyzed in several epidemiologic studies and estimated to be approximately 7%. Follow-up studies estimate that 60% to 85% of these children will meetADHD criteria as teenagers. Several algorithms guide treatment of ADHD, including the American Association of Child and Adolescent Psychiatry Practice Parameters for ADHD and the Texas Department of Health Services MedicationAlgorithm Project. Medications, including D,L-methylphenidate (MPH), dextroamphetamine, mixed amphetamine salts, and atomoxetine are FDA approved for the treatment of ADHD and considered first-line treatments. In several studies, these agents were very effective in treating symptoms ofADHD,with clinical response rates of up to 70% versus 4% to 30% with placebo. The effect size of stimulant treatment relative to placebo is 1.0. MPH and amphetamine preparations were compared and found equal in efficacy. Long-acting formulations are equal in efficacy to immediaterelease preparations and have the advantage of increasing adherence with once-daily dosing. Dosage may be titrated to After participating in this activity, the psychiatrist should be better able to:","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2010-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000377465.94323.2d","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61611921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Pharmacotherapy of First‐Episode Schizophrenia 首发精神分裂症的药物治疗

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2010-06-01 DOI: 10.1097/01.IDT.0000372139.52401.97

E. Liffick, A. Breier

{"title":"Pharmacotherapy of First‐Episode Schizophrenia","authors":"E. Liffick, A. Breier","doi":"10.1097/01.IDT.0000372139.52401.97","DOIUrl":"https://doi.org/10.1097/01.IDT.0000372139.52401.97","url":null,"abstract":"approximately 1% of the world’s population. It is characterized by abnormal perceptual experiences, lack of expressiveness, social withdrawal, and cognitive difficulties. Onset of the disease typically occurs in late adolescence to early adulthood with prodromal symptoms—those being present prior to diagnosis of overt illness—noted years earlier in some patients. During these critical years of social, academic, and vocational development, many individuals with schizophrenia experience symptoms that hinder their ability tomeet personal goals. Symptomsmay be both terrifying and disabling. The disease is also associated with significant social costs. These include high rates of suicide, incarceration, unemployment, homelessness, and substance abuse. An additional concern is the life-shortening capacity of the disorder, primarily from cardiovascular disease and suicide. Individuals with schizophrenia have up to a 20% reduction in life expectancy comparedwith the general population. Given the substantial clinical and societal burden associated with schizophrenia, new approaches to manage this illness are urgently needed. After completing this CME activity, clinicians should be able to provide evidence based treatment for individuals early in the course of a psychotic illness.","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000372139.52401.97","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61612305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Glutamate and the Treatment of Obsessive-Compulsive Disorder. 谷氨酸与强迫症的治疗。

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2010-05-01 DOI: 10.1097/01.IDT.0000371059.45965.88

Frank P Macmaster, David R Rosenberg

引用次数: 4

Glutamate and the Treatment of Obsessive‐Compulsive Disorder 谷氨酸和强迫症的治疗

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2010-05-01 DOI: 10.1097/01.IDT.0000371058.38341.b3

F. Macmaster, D. Rosenberg

引用次数: 3

Transcranial Magnetic Stimulation for the Treatment of Major Depression: Clinical, Economic, and Practical Issues Part I 经颅磁刺激治疗重度抑郁症:临床、经济和实际问题第一部分

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2010-04-01 DOI: 10.1097/01.IDT.0000369508.83887.DB

M. Demitrack

引用次数: 0

Use of Psychiatric Drugs in Patients With Hepatitis C Review and Recommendations 丙型肝炎患者使用精神药物的回顾和建议

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2010-03-01 DOI: 10.1097/01.IDT.0000368372.20840.B5

J. Onate

{"title":"Use of Psychiatric Drugs in Patients With Hepatitis C Review and Recommendations","authors":"J. Onate","doi":"10.1097/01.IDT.0000368372.20840.B5","DOIUrl":"https://doi.org/10.1097/01.IDT.0000368372.20840.B5","url":null,"abstract":"ease that is often asymptomatic for decades. Three hundred million people worldwide and 3.2 million in the United States are estimated to be infected with hepatitis C virus (HCV), which is a single-stranded ribonucleic acid virus. It is a leading indication for liver transplantation worldwide and is associated with high rates of cirrhosis and hepatocellular carcinoma. Chronic, active hepatitis C is also associated with high rates of substance use and mood, anxiety, and personality disorders. Diagnosis is first established by screening for anti-HCV antibodies and confirmed with a viral load and genotyping. There are six genotypes and many subgroups of hepatitis C. Genotypes 1a and 1b are the most common in the United States, and genotypes 2 and 3 are responsible for most cases elsewhere in the world. Patients with severe mental illness are at high risk of infection, especially in the presence of comorbid substance use.Although intravenous drug use is the highest risk factor, use of crack cocaine also substantially increases the risk of hepatitis C transmission. Additionally, sex-trade involvement and impulsivity found in substance abusers promotes high-risk behaviors resulting in increased transmission of viral hepatitis, HIV, and other sexually transmitted diseases (Table 1). There is evidence of an unrecognized epidemic of hepatitis C in the population with severe mental illness. Because patients with chronic hepatitis C often have normal liver function tests (LFTs) and aminotransferase levels, those with any history of intravenous drug use, crack cocaine use, or high-risk sexual behavior should be offered screening. Infected patients need a complete medical evaluation to rule out hepatic insufficiency and hepatocellular carcinoma. Those with hepatitis C should also be educated regarding the risk factors for transmission and treatment After participating in this activity, the psychiatrist should be better able to:","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2010-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000368372.20840.B5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61611517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toward Early, Personalized, Rational Polypharmacy In Psychiatry: A Tri‐Dimensional Approach 精神病学的早期、个性化、理性综合用药:一种三维方法

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2010-02-01 DOI: 10.1097/01.IDT.0000366925.86837.fe

A. Niculescu, L. Hulvershorn

引用次数: 8

A Novel Treatment Option for Schizophrenia 一种治疗精神分裂症的新方法

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2010-01-01 DOI: 10.1097/01.IDT.0000365317.93432.c1

Jeffrey Rado, P. Janicak

引用次数: 4

Asenapine: A Review of the Data 阿塞那平:数据回顾

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2009-12-01 DOI: 10.1097/01.IDT.0000363156.07272.2e

P. Janicak, Jeffrey Rado

{"title":"Asenapine: A Review of the Data","authors":"P. Janicak, Jeffrey Rado","doi":"10.1097/01.IDT.0000363156.07272.2e","DOIUrl":"https://doi.org/10.1097/01.IDT.0000363156.07272.2e","url":null,"abstract":"of the two recently approved antipsychotics in the United States. A subsequent issue will report on iloperidone. Asenapine is the latest agent to receive FDAapproval for both the acute treatment of schizophrenia andmanic or mixed episodes associated with bipolar I disorder in adults. It is marketed in the United States under the trade name Saphris (Schering Corp.) and is administered sublingually (SL). The recommended starting and target dose for schizophrenia is 5 mg twice daily, and the recommended starting dose for bipolar I disorder is 10 mg twice daily. The safety of asenapine at doses greater than 10 mg SLBID has not been assessed in clinical trials. This review will consider asenapine’s neuroreceptor profile, the data to support its utility in managing various symptoms associated with these disorders, and how asenapinemay distinguish itself from other agents in its class. PHARMACODYNAMICS Asenapine is a dibenzo-oxepino pyrrole, possessing a unique structure and a “broader spectrum” of neuroreceptor activity with differing affinity and antagonistic properties from other agents in its class (e.g., risperidone, olanzapine) (Figure 1). In this context, it has affinity and specificity for various receptors, including:","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000363156.07272.2e","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61611451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3